Arcutis Biotherapeutics (NASDAQ:ARQT) CFO Sells $31,661.01 in Stock

Key Points

• CFO Latha Vairavan sold 1,341 shares for $31,661.01 in a Rule 10b5-1 plan on May 4 to cover tax withholding from vested awards, leaving her with 86,413 shares (a 1.53% reduction).
• ZORYVE net product revenue was $105.4M, up ~65% year‑over‑year, and the company said it maintained positive operating cash flow while advancing regulatory and pipeline milestones (sNDA for infants, pediatric enrollment complete, and first‑in‑human ARQ‑234 studies started).
• Quarterly results: EPS missed estimates (reported -$0.09 vs. -$0.02 expected) despite revenue slightly beating consensus, and analysts maintain a consensus "Moderate Buy" with an average price target of $34.00.

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) CFO Latha Vairavan sold 1,341 shares of Arcutis Biotherapeutics stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $23.61, for a total transaction of $31,661.01. Following the completion of the transaction, the chief financial officer directly owned 86,413 shares in the company, valued at approximately $2,040,210.93. This represents a 1.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Latha Vairavan also recently made the following trade(s):

• On Monday, March 2nd, Latha Vairavan sold 2,853 shares of Arcutis Biotherapeutics stock. The stock was sold at an average price of $25.18, for a total transaction of $71,838.54.

Arcutis Biotherapeutics Stock Performance

NASDAQ:ARQT traded up $0.75 during midday trading on Wednesday, reaching $24.17. The stock had a trading volume of 1,381,968 shares, compared to its average volume of 1,329,167. Arcutis Biotherapeutics, Inc. has a 1-year low of $12.42 and a 1-year high of $31.77. The firm's fifty day simple moving average is $23.82 and its 200-day simple moving average is $25.75. The company has a debt-to-equity ratio of 0.57, a current ratio of 3.17 and a quick ratio of 2.99. The stock has a market capitalization of $3.02 billion, a P/E ratio of -172.63 and a beta of 1.58.

Arcutis Biotherapeutics (NASDAQ:ARQT - Get Free Report) last released its earnings results on Wednesday, May 6th. The company reported ($0.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.07). Arcutis Biotherapeutics had a negative return on equity of 10.26% and a negative net margin of 4.29%.The firm had revenue of $105.40 million for the quarter, compared to analyst estimates of $103.68 million. On average, equities research analysts forecast that Arcutis Biotherapeutics, Inc. will post 0.18 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have commented on the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Arcutis Biotherapeutics in a research report on Friday, March 27th. Guggenheim raised their price objective on shares of Arcutis Biotherapeutics from $34.00 to $35.00 and gave the stock a "buy" rating in a research note on Friday, February 27th. HC Wainwright boosted their target price on shares of Arcutis Biotherapeutics from $30.00 to $34.00 and gave the stock a "buy" rating in a research report on Thursday, February 26th. TD Cowen upped their target price on shares of Arcutis Biotherapeutics from $30.00 to $35.00 and gave the company a "buy" rating in a research note on Thursday, February 26th. Finally, Needham & Company LLC increased their price target on shares of Arcutis Biotherapeutics from $31.00 to $36.00 and gave the company a "buy" rating in a report on Thursday, February 26th. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $34.00.

Institutional Trading of Arcutis Biotherapeutics

Hedge funds have recently modified their holdings of the company. Johnson Investment Counsel Inc. bought a new stake in shares of Arcutis Biotherapeutics during the third quarter valued at approximately $30,000. SBI Securities Co. Ltd. boosted its stake in Arcutis Biotherapeutics by 325.4% during the fourth quarter. SBI Securities Co. Ltd. now owns 1,089 shares of the company's stock worth $32,000 after buying an additional 833 shares in the last quarter. Global Retirement Partners LLC acquired a new stake in Arcutis Biotherapeutics during the fourth quarter worth $35,000. EverSource Wealth Advisors LLC increased its holdings in Arcutis Biotherapeutics by 124.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,261 shares of the company's stock valued at $37,000 after buying an additional 698 shares during the period. Finally, NewEdge Advisors LLC raised its stake in shares of Arcutis Biotherapeutics by 209.0% in the 4th quarter. NewEdge Advisors LLC now owns 1,545 shares of the company's stock valued at $45,000 after buying an additional 1,045 shares in the last quarter.

Key Stories Impacting Arcutis Biotherapeutics

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Q1 product momentum — ZORYVE net product revenue was $105.4M, up ~65% year‑over‑year and above consensus revenue; company said it maintained positive operating cash flow and highlighted continued branded non‑steroidal share gains. Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Regulatory and pipeline progress — submitted an sNDA to expand ZORYVE for infants (3–24 months), completed enrollment in the ZORYVE foam pediatric MUSE trial, and started first‑in‑human studies of ARQ‑234. These catalysts support longer‑term growth expectations. Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Commercial build — expanded the dermatology sales force and is building a primary care/pediatrics organization, which could broaden ZORYVE adoption. Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Analyst stance — broker consensus remains a “Moderate Buy,” supporting investor sentiment around upside to the current share price. Arcutis Receives Consensus Recommendation of "Moderate Buy"
• Neutral Sentiment: Insider sales disclosed — several executives and a director sold shares recently (executed under pre‑arranged Rule 10b5‑1 plans and largely to cover taxes on vested awards), which is typical after vesting and less likely to signal negative insider sentiment. Representative SEC filing: Todd Watanabe Form 4

Arcutis Biotherapeutics Company Profile

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company's research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.